跳至主要内容
临床试验/NCT05964907
NCT05964907进行中(未招募)不适用

Optimizing Phototesting and Investigating Photobiology of Visible Light

Henry Ford Health System2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2021年10月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
14
试验地点
2
主要终点
Pigmentation assessment for all 14 participants.

研究概览

简要总结

Specific Aim 1: To determine the impact of spectral composition of the VL+UVA1 source on the associated biologic effects.

Specific Aim 2: To investigate differential responses of subjects with different skin phototypes to VL+UVA1, including immediate and delayed erythema and pigmentation, and photodamage.

详细描述

The design of the study consists of a total of 4 visits within a two week period. The first visit consists of VL+UVA1 irradiation with different light source on the opposite site of patients' back. A combination of non-invasive measurements (e.g., photography, redness and color changes of the skin using colorimetry and diffuse reflectance spectrometry) will be conducted throughout the 4 visits. Biopsies will be taken at various time points.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy individuals age 18 and older
  • Fitzpatrick skin phototype (SPT) I-VI, 7 with SPT I-III and 7 with SPT IV-VI, with normal healthy skin
  • Able to understand the requirements of the study and its associated risks
  • Able to complete and sign a consent form
  • Willing and able to refrain from any medications or herbal supplements during the duration of the study, unless permitted by the investigator
  • Agrees to refrain from using any new topical skin care products, laundry detergents, or fragrances while participating in the study
  • Has not had excessive sun exposure for 7 days prior to enrollment in the study

排除标准

  • Recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post-inflammatory hyperpigmentation
  • History of relevant skin conditions such as atopic dermatitis, eczema, or sunburn on any part of the body
  • History of photodermatoses or photosensitivity disorders
  • History of melanoma or non-melanoma skin cancers
  • Use of tanning parlors or exposure of the irradiated sites to sun light during the duration of the study
  • Use of topical or systemic treatment that is likely to interfere with assessment, study results, or pose safety concerns
  • Subjects with a tendency to bleed excessively
  • Known allergies to anesthetics (lidocaine) or anaphylaxis treatment (epinephrine)
  • History of hypertrophic scarring or keloid formation
  • Use of any photosensitizing medication within the visible light range or additional medication at the discretion of the investigator [examples include - but not limited to - thiazide diuretics, regular use of NSAIDs, hydroxychloroquine, or voriconazole
  • A woman who is lactating, pregnant, or planning to become pregnant

研究组 & 干预措施

VL+UVA1

Other

Participants will be treated with VL + UVA1 light source

干预措施: Light Source B: Visible Light solar simulator (VL + UVA1) (Device)

VL+UVA1

Other

Participants will be treated with VL + UVA1 light source

干预措施: Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1) (Device)

结局指标

主要结局

Pigmentation assessment for all 14 participants.

时间窗: Visit 1 (day 0)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation 1. Almost clear of hyperpigmentation 2. Mild, but noticeable hyperpigmentation 3. Moderate hyperpigmentation (medium brown) 4. Severe hyperpigmentation (dark brown) 5. Very severe hyperpigmentation (very dark brown to almost black)

Erythema assessment for all 14 participants.

时间窗: Visit 1 (Day 0)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema 1. Almost clear of erythema 2. Mild, but noticeable erythema 3. Moderate erythema (pink), no sharp borders 4. Severe erythema (dark pink), sharp borders 5. Very severe erythema (very dark pink to almost red)

Erythema assessment for all participants

时间窗: Visit 2 (Day 1)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema 1. Almost clear of erythema 2. Mild, but noticeable erythema 3. Moderate erythema (pink), no sharp borders 4. Severe erythema (dark pink), sharp borders 5. Very severe erythema (very dark pink to almost red)

Erythema assessment

时间窗: Visit 3 (Day 7)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema 1. Almost clear of erythema 2. Mild, but noticeable erythema 3. Moderate erythema (pink), no sharp borders 4. Severe erythema (dark pink), sharp borders 5. Very severe erythema (very dark pink to almost red)

Pigmentation assessment for all 14

时间窗: Visit 4 (Day 14)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation 1. Almost clear of hyperpigmentation 2. Mild, but noticeable hyperpigmentation 3. Moderate hyperpigmentation (medium brown) 4. Severe hyperpigmentation (dark brown) 5. Very severe hyperpigmentation (very dark brown to almost black)

Erythema assessment for all 14 participants

时间窗: Visit 4 (Day 14)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Erythema assessment for 14 participants

时间窗: Visit 4 (Day 14)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema 1. Almost clear of erythema 2. Mild, but noticeable erythema 3. Moderate erythema (pink), no sharp borders 4. Severe erythema (dark pink), sharp borders 5. Very severe erythema (very dark pink to almost red)

Pigmentation assessment for all 14 participants..

时间窗: Visit 1 (day 0)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Pigmentation assessment for all 14 participants

时间窗: Visit 4 (Day 14)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Pigmentation assessment for 14 participants

时间窗: Visit 3 (Day 7)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation 1. Almost clear of hyperpigmentation 2. Mild, but noticeable hyperpigmentation 3. Moderate hyperpigmentation (medium brown) 4. Severe hyperpigmentation (dark brown) 5. Very severe hyperpigmentation (very dark brown to almost black)

Erythema assessment for all 14 participants

时间窗: Visit 1 (Day 0)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Erythema assessment for all 14 participants

时间窗: Visit 2 (Day 1)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Erythema assessment for all 14 participants

时间窗: Visit 3 (Day 7)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Pigmentation assessment for all 14

时间窗: Visit 2 (Day 1)

Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation 1. Almost clear of hyperpigmentation 2. Mild, but noticeable hyperpigmentation 3. Moderate hyperpigmentation (medium brown) 4. Severe hyperpigmentation (dark brown) 5. Very severe hyperpigmentation (very dark brown to almost black)

Pigmentation assessment for all 14 participants

时间窗: Visit 2 (Day 1)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Pigmentation assessment for all 14 participants

时间窗: Visit 3 (Day 7)

Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L\* and a\* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L\* and b\* by using ITA = \[arctan (L\* - 50)/b\*\] X 180/Π)\]. Colorimetry: Decrease in L\* and ITA indicates greater pigmentation. Increase in a\* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

次要结局

  • RNA sequencing for 8 participants(Visit 2 (Day 1))
  • Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants(Visit 3 (Day 7))
  • Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants(Visit 1 (Day 0))
  • Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants(Visit 2 (Day 1))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Indermeet Kohli

Associate Scientist

Henry Ford Health System

研究点 (2)

Loading locations...

相似试验